Sunshine Biopharma Inc.: net property, plant and equipment
Net property, plant and equipment for Sunshine Biopharma Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Sunshine Biopharma Inc. financial histories
What this measure means
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
Exact concept: us-gaap:PropertyPlantAndEquipmentNet. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2014-12-31 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 557,370 | USD | 2026-04-03 | 10-K · 0001683168-26-002644 |
| At date | 2024-12-31 | 546,055 | USD | 2026-04-03 | 10-K · 0001683168-26-002644 |
| At date | 2023-12-31 | 365,868 | USD | 2025-04-01 | 10-K · 0001683168-25-002184 |
| At date | 2022-12-31 | 394,249 | USD | 2024-03-28 | 10-K · 0001683168-24-001818 |
| At date | 2021-12-31 | 7,061 | USD | 2023-04-04 | 10-K · 0001683168-23-002128 |
| At date | 2020-12-31 | 19,531 | USD | 2022-03-21 | 10-K · 0001683168-22-001788 |
| At date | 2019-12-31 | 32,456 | USD | 2021-03-30 | 10-K · 0001654954-21-003507 |
| At date | 2018-12-31 | 45,124 | USD | 2020-05-01 | 10-K · 0001654954-20-004731 |
| At date | 2017-12-31 | 59,996 | USD | 2019-04-12 | 10-K · 0001654954-19-004354 |
| At date | 2016-12-31 | 5,944 | USD | 2018-04-02 | 10-K · 0001654954-18-003495 |
| At date | 2015-12-31 | 4,314 | USD | 2017-04-17 | 10-K · 0001654954-17-003365 |
| At date | 2014-12-31 | 0 | USD | 2016-03-25 | 10-K · 0001354488-16-006700 |
Related financial histories
- Sunshine Biopharma Inc.: total assets
- Sunshine Biopharma Inc.: total liabilities
- Sunshine Biopharma Inc.: stockholders equity
- Sunshine Biopharma Inc.: cash and cash equivalents
- Sunshine Biopharma Inc.: net income or loss
- Sunshine Biopharma Inc.: operating cash flow
- Sunshine Biopharma Inc.: capital expenditure payments
- Sunshine Biopharma Inc.: revenue
- Sunshine Biopharma Inc.: financing cash flow
- Sunshine Biopharma Inc.: investing cash flow
- Sunshine Biopharma Inc.: retained earnings or deficit
- Sunshine Biopharma Inc.: basic weighted-average shares
- Sunshine Biopharma Inc.: diluted weighted-average shares
- Sunshine Biopharma Inc.: basic earnings per share
- Sunshine Biopharma Inc.: diluted earnings per share
- Sunshine Biopharma Inc.: income tax expense or benefit
- Sunshine Biopharma Inc.: share-based compensation expense
- Sunshine Biopharma Inc.: operating income or loss
- Sunshine Biopharma Inc.: current assets
- Sunshine Biopharma Inc.: interest expense
- Sunshine Biopharma Inc.: current liabilities
- Sunshine Biopharma Inc.: current accounts payable
- Sunshine Biopharma Inc.: goodwill carrying amount
- Sunshine Biopharma Inc.: net finite-lived intangible assets
- Sunshine Biopharma Inc.: net current accounts receivable
- Sunshine Biopharma Inc.: common-stock repurchase payments
- Sunshine Biopharma Inc.: net inventory
- Sunshine Biopharma Inc.: gross profit
- Sunshine Biopharma Inc.: cost of revenue
- Sunshine Biopharma Inc.: research and development expense
Inspect the source
- Entity
- Sunshine Biopharma Inc. / CIK 0001402328
- Captured
- 2026-09-20T08:00:47.083Z
- SEC response SHA-256
089eb69bd01c2bc993f5073ccdb651eba31ddb7f7ea640d657095dcd4ddd9932
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001402328.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))